Gadolinium chelate compounds for use in magnetic resonance imaging

US11491245B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Markus Berger · Berlin, DE
• Jessica Lohrke · Berlin, DE
• Christoph-Stephan Hilger · Berlin, DE
• Gregor Jost · Berlin, DE
• Thomas Frenzel · Berlin, DE
• Detlev Suelzle · Berlin, DE
• Johannes Platzek · Berlin, DE
• Olaf Panknin · Berlin, DE
• Hubertus Pietsch · Kleinmachnow, DE

Key dates

• Filing date: Jul 27, 2020
• Grant date: Nov 8, 2022
• Expiry date: Nov 21, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D257/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.